LifeSci Advisors Continues Expansions with New Boston Office
Providing Investor Relations, Public Relations, Corporate Communications
and Capital Markets Advisory Services to Greater Boston and Cambridge Life Sciences Companies
NEW YORK, Oct. 12, 2017 (GLOBE NEWSWIRE) -- LifeSci Advisors, an investor relations and corporate communications firm focused on the life sciences sector ("LifeSci"), today announces the opening of an office in Boston, enhancing its presence in the Greater Boston and Cambridge communities. The office will be managed by Hans Vitzthum, managing director with LifeSci Advisors.
"Massachusetts has long been a hub for groundbreaking biotech research and drug development in the life sciences industry, so it was a natural decision to expand our local presence to the Boston area," said Michael Rice, President and co-founder of LifeSci Advisors. "Our Boston-based team has long-standing relationships within the local investment and life sciences communities and looks forward to more efficiently delivering our extensive service offering to the Greater Boston and Cambridge biotech and pharma communities."
In addition to its Boston location, LifeSci has a physical presence in New York, where the firm is headquartered, Chicago, Philadelphia, London, Geneva and Tel Aviv. The firm's capabilities include global corporate access through non-deal roadshows and targeted investor and KOL events, corporate communications, and corporate governance consulting. Through its affiliates, LifeSci also provides its clients capital markets solutions, equity research coverage, and public relations services.
Vitzthum has more than 25 years' experience in institutional sales and healthcare research product management at Leerink Partners, Cowen & Co., and Lazard Capital Markets. He spent 12 years running the morning research call at two investment banks and has served as the "Deal Captain" on more than 100 healthcare IPOs and secondary offerings. Vitzthum has worked in healthcare research product management for the past 15 years and has developed extensive and long-standing relationships within the institutional investment community. He has an Applied Baccalaureate from Columbia College.
LifeSci Advisors, LLC (www.lifesciadvisors.com) is the largest investor relations consultancy in the life sciences industry, founded to provide companies with a multi-faceted approach to investor communications and outreach. With a global focus and reach, the firm provides the highest quality service for its clients through its deep sector specialization. LifeSci's team of MDs and PhDs enables the firm to better understand clients' R&D, regulatory and commercial strategies, and its team of financial services, investor relations and public relations specialists helps clients effectively communicate to the marketplace. This combination of life sciences, financial services, and investor relations competencies allows LifeSci Advisors to provide an invaluable and unique service offering to clients.
LifeSci Partners (www.lifescipartners.com) is the leading provider of consulting services in the areas of investor relations, public relations, corporate communications and capital markets advisory. Combining deep domain expertise in the life sciences with decades of experience in capital markets and public relations, LifeSci Partners delivers unparalleled services to life sciences companies globally.
For further information, please contact:
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LifeSci Advisors, LLC via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Algeco Announces Third Quarter 2018 Financial Results Conference Call19.11.2018 16:04 | Pressemelding
LONDON, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Algeco Investments B.V. (together with its subsidiaries, “Algeco”), the leading global business services provider of modular space, secure portable storage solutions and remote workforce accommodations, today announced that it will hold its third quarter 2018 financial results conference call on Monday 26 November 2018 at 3:00pm GMT (10:00 a.m., Eastern Time). To access the call, please dial: UK: +44 3333000804 or 08003589473 (UK toll free) US: +1 6319131422 or +1 855 85 70686 (US toll free) and enter participant PIN code 84969282# approximately ten minutes prior to the start of the call. You will be placed on hold until the event begins. The conference call will also be broadcast over the internet with an accompanying slide presentation. To join the web conference, go to https://event.on24.com/wcc/r/1884864/AA4F091A2F921FE451DDBD688F19B26F. Please enter your name, email address and company to join the call. The customer service team can be rea
Bombardier to supply 19 OMNEO Premium trains for the Hauts-de-France region’s intercity lines19.11.2018 15:31 | Pressemelding
OMNEO Premium will provide about 25% more seating capacity to intercity travelers between Paris and the Hauts-de-France region A comfortable double-deck train offering new features such as newly-designed spacious seats, easier platform access and ample baggage space BERLIN, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Note to editors: To view the photo associated with this press release, please visit the following link: http://www.globenewswire.com/NewsRoom/AttachmentNg/683009f7-6c0e-4ab2-8800-5bb87399c7e0 Mobility technology leader Bombardier Transportation announced today that it received an order for 19 BOMBARDIER OMNEO Premium double-deck trains from the French National Railway Corporation, Société nationale des chemins de fer français (SNCF) on behalf of the Hauts-de-France region. This call-off order is part of the contract signed in 2010 with SNCF to provide up to 860 double deck-trains to French regions and is valued at approximately 256 million euro ($291 million US), including price esc
CP Kelco Announces Plans to Invest in Specialty Biogums Capabilities and Capacity Expansion19.11.2018 14:15 | Pressemelding
ATLANTA, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In response to the strong global demand for specialty Biogums products, CP Kelco announced today its plans to invest in building capabilities and expanding production capacity. As a leading global producer and innovator of hydrocolloid solutions, CP Kelco is reinforcing its commitment to three Biogums product lines – gellan gum, specialty xanthan gum and diutan gum – through these key operational initiatives: Adding gellan gum production capabilities in the company’s Wulian, China facility to support growth in the Asia Pacific region; Expanding the overall capacity of the Wulian, China facility to support growth across all three specialty Biogums product lines; and Expanding the recently added gellan gum production capacity in the company’s Okmulgee, Oklahoma, USA facility. In addition to the planned investments in new production capabilities and capacity, CP Kelco is equally committed to ensuring its Biogums products meet the high standards o
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan19.11.2018 14:00 | Pressemelding
SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submission of the LeukoStrat® CDx FLT3 Mutation Assay to the PMDA (Pharmaceuticals and Medical Devices Agency) as the companion diagnostic for quizartinib, which follows Daiichi Sankyo’s PMDA application for quizartinib in Japan. Invivoscribe developed the LeukoStrat CDx FLT3 Mutation Assay in partnership with Daiichi Sankyo as the companion diagnostic that bridges to the global phase 3 QuANTUM-R clinical trial (Europe, United States, Asia excluding Japan) in patients with relapsed/refractory FLT3 ITD AML. Together, QuANTUM-R clinical trial and open-label phase 2 study of quizartinib (Japan) support the Daiichi Sankyo New Drug Application (NDA) to Japan’s MHLW/PMDA for marketing approval of quizartinib for the treatment of adult patients with relapsed/refractory FLT3 ITD acute myeloid leukemia (AML). This submission complements Invivoscribe’s prior
Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers19.11.2018 14:00 | Pressemelding
Findings suggest expanded therapeutic window and significantly improved cardiovascular safety margin compared to formulation used in Phase 2b trial All doses tested up to 256 milligrams appear safe and well tolerated with no significant changes in cardiac repolarization and QTc intervals Tested formulation is used in ongoing Phase 3 trial Data to be reviewed at Minerva’s roluperidone update and key opinion leader event on Tuesday, November 20, 2018 beginning at 8:00 a.m. Eastern Time in New York WALTHAM, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the results from a prospective, double-blind, placebo-controlled, randomized single-escalating dose study in healthy subjects to evaluate the investigational drug roluperidone as monotherapy administered at nine ascending doses (16, 32, 64, 96, 128, 160, 19
Clutch Ranks SoftServe Among the Top Data Analytics Companies in Ukraine19.11.2018 13:00 | Pressemelding
AUSTIN, Texas, Nov. 19, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, announces it has been named a top data analytics consulting company in Ukraine for its high-quality service in technology transformation consulting by Clutch, a leading B2B research, ratings, and reviews company based in Washington D.C. SoftServe ranked ninth out of more than 140 firms in the data analytics category. Clutch determines its industry leader rankings by using a methodology that evaluates companies based on industry expertise and the ability to deliver. Additional criteria includes services offered, types of clients, case studies, brand reputation, and visibility within the target market. “As part of Clutch’s service, we provide business to business firms the opportunity to evaluate companies and their competitors so that they can find the best partner to meet their needs,” said Jackie Faselt, Business Analyst at Clutch. “SoftServe’s technical expertise and positi
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom